Cadrenal Therapeutics enters ATM agreement with H.C. Wainwright for up to $5.14M in common stock

Cadrenal Therapeutics, Inc.

Entered ATM agreement with H.C. Wainwright to sell up to $5,143,730 of common stock from time to time.
Sales agent compensation is 3.0% of gross proceeds; no minimum sale obligation.
Offering subject to effectiveness of Form S-3 registration statement filed March 11, 2024.
Company can terminate agreement at any time; Wainwright can terminate on material adverse change.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cadrenal Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $5,143,730 (effective 2024-03-11).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: $5,143,730
Effective: 2024-03-11

Exact text from the filing

On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation, (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-021512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.